GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients

GNT Pharma Inc. reported that the Korea Ministry of Food and Drug Safety has approved the Investigational New Drug Application for a phase III study of nelonemdaz for acute ischemic stroke patients.